DLL3-Upregulated Solid Tumors
IDYAIDEAYA BiosciencesCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for IDE849 + IDE161 (TOP1-PARG Combination) in DLL3-Upregulated Solid Tumors. The expected timing is based on the latest available company guidance and may change.
03/30/26:- FPI in Ph1 IDE849+IDE161 combo; clinical data update expected H2 2026. 05/05/26:- Reiterated FPI in IDE849 plus IDE161 Ph1 combo trial; study designed to evaluate TOP1-PARG synergy. 08/04/26:- IDE849+IDE161 Ph1 combo ongoing in DLL3-upregulated tumors.
Verification
Confirm timing and program details against the company announcement or filing.